Shilpa Medicare has received a warning letter from US Food and Drug Administration (USFDA) for its Jadcherla facility, Telangana. The warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility. The company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.
The company currently has three manufacturing facilities approved by USFDA - one formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the USFDA at this point of time.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
